Fig. 7: pNaktide mimics the suppressive effects of exogenous ATP1A1 in ccRCC cells. | Cancer Gene Therapy

Fig. 7: pNaktide mimics the suppressive effects of exogenous ATP1A1 in ccRCC cells.

From: pNaktide reverses metabolic reprogramming and disease progression of ATP1A1-deficiency clear cell renal cell carcinoma

Fig. 7

A The glycolytic capacity and reserve in 769-P cells treated with pNaktide were assessed using the Seahorse XF analyzer. B The OXPHOS levels, characterized by ATP production, maximal respiration, and spare respiratory capacity in 769-P cells treated with pNaktide, were detected by Seahorse XF. Apoptosis in 769-P (C) and Caki-1 cells (D) treated with pNaktide was analyzed by flow cytometry. E The intracellular ROS levels in 769-P and Caki-1 cells treated with varying concentrations of pNaktide were detected by the mitochondria-targeted superoxide probe MitoSO™ Red. F The levels of SRC, p-SRC, ERK1/2, p-ERK1/2, cyto c, and cleaved caspase 9 in 769-P and Caki-1 cells treated with pNaktide in a final concentration of 5 μM were detected by WB.

Back to article page